Your browser doesn't support javascript.
loading
Late-onset multiple sclerosis in Iran: A report on demographic and disease characteristics.
Ghadiri, Fereshteh; Sahraian, Mohammad Ali; Razazian, Nazanin; Ashtari, Fereshteh; Poursadeghfard, Maryam; Nabavi, Seyed Massood; Navardi, Samira; Baghbanian, Seyed Mohammad; Shaygannejad, Vahid; Harirchian, Mohammad Hossein; Beladimoghadam, Nahid; Majdinasab, Nastaran; Hosseini, Samaneh; Azimi, Amirreza; Kamali, Hoda; Sharifipour, Ehsan; Hosseini Nejad Mir, Nahid; Bayati, Asghar; Nahayati, Mohammad Ali; Heidari, Hora; Mozhdehipanah, Hossein; Ghalyanchi Langroodi, Hamidreza; Jalali, Nazanin; Ayoubi, Saeideh; Asadollahzadeh, Elnaz; Ebadi, Zahra; Eskandarieh, Sharareh; Naser Moghadasi, Abdorreza.
Afiliación
  • Ghadiri F; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Sahraian MA; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Razazian N; Department of Neurology, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Ashtari F; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Poursadeghfard M; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Nabavi SM; Department of Regenerative Medicine, Royan Institute for Stem Cell Technology and Biology, Tehran, Iran.
  • Navardi S; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Baghbanian SM; Department of Neurology, Booalicina Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
  • Shaygannejad V; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Harirchian MH; Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Beladimoghadam N; Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Majdinasab N; Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Hosseini S; Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Azimi A; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Kamali H; Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran.
  • Sharifipour E; Department of Neurology, School of Medicine, Neuroscience Research Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
  • Hosseini Nejad Mir N; Department of Internal Medicine, School of Medicine, Shohadaye Ashayer Hospital, Lorestan, University of Medical Sciences, Khorramabad, Iran.
  • Bayati A; Department of Neurology, Shahrekord University of Medical Sciences and Health Services, Shahrekord, Iran.
  • Nahayati MA; Department of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Heidari H; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Mozhdehipanah H; Department of Neurology, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Ghalyanchi Langroodi H; Clinical Development and Research Unit of Ghaem Hospital, Gilan University of Medical Sciences, Rasht. Iran.
  • Jalali N; Department of Neurology, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
  • Ayoubi S; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Asadollahzadeh E; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Ebadi Z; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Eskandarieh S; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: sh_eskandarieh@yahoo.com.
  • Naser Moghadasi A; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: abdorrezamoghadasi@gmail.com.
Mult Scler Relat Disord ; 70: 104493, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36638768
BACKGROUND: Today, it is estimated that around 5% of multiple sclerosis (MS) patients are in the late-onset category (age at disease onset ≥ 50). Diagnosis and treatment in this group could be challenging. Here, we report the latest update on the characteristics of Iranian patients with late-onset MS (LOMS). METHODS: This cross-sectional study used the information provided by the nationwide MS registry of Iran (NMSRI). The registrars from 14 provinces entered data of patients with a confirmed diagnosis of MS by neurologists. Patients with disease onset at or later than 50 years of age were considered LOMS. RESULTS: Of 20,036 records, the late-onset category included 321 patients (1.6%). The age-standardized LOMS prevalence was around 75 per 100,000 people. 215 patients (67%) were female. Median Expanded Disability Status Scale (EDSS) was 3 (interquartile range: 1.5-5). The majority of the cases (56%) suffered from relapsing-remitting (RR) course while 20% were diagnosed with primary progressive (PP) MS. Significantly higher proportion of male sex, PPMS, and higher EDSS were seen in the late-onset group compared with early-onset and adult-onset cases (p-value < 0.05). Seventy-five (23%) patients did not receive any disease-modifying treatment. DISCUSSION: The more prominent degenerative pathology of LOMS may be the underlying mechanism of the observed differences in comparison to non-LOMS. CONCLUSION: There are substantial differences and knowledge gaps regarding LOMS which could be the subject of further research.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esclerosis Múltiple Crónica Progresiva / Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Mult Scler Relat Disord Año: 2023 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Esclerosis Múltiple Crónica Progresiva / Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Mult Scler Relat Disord Año: 2023 Tipo del documento: Article País de afiliación: Irán